Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
Pfizer Inc. says third-quarter profit dropped 19 per cent as generic competition continued to cut sales, while operational expenses, taxes and charges all rose.
The maker of Lyrica for fibromyalgia says net income was $2.59 billion, or 39 cents per share, down from $3.21 billion, or 43 cents per share, a year earlier.
Excluding one-time items, the world’s second-largest drugmaker says net income would have been $3.86 billion, or 58 cents per share. Analysts surveyed by FactSet expected 56 cents per share.
Revenue totalled $12.64 billion, down 2 per cent from $12.95 billion a year ago. Analysts expected $12.69 billion.
New York-based Pfizer raised the lower end of its 2013 profit forecast by a nickel and now expects $2.15 to $2.20 per share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.